505(b)(2) & OTC speed with de-risked safety
Consumer, Rx, hospital, injectable applications
Addressing upstream inflammation offers outsized returns relative to today’s narrow symptom-based markets
Where you engage matters less than when—and the time is now. PAIR’s dual-molecule platform is designed for integration across R&D pipelines, hospital formularies, consumer health channels, and global supply chains.
Whether through co-development, licensing, strategic investment, we welcome conversations with those ready to help move the line of health forward.
We are also exploring strategic partnerships in Veterinary Health – where Sen-Jam science could make a tail-wagging difference. Reach out if this aligns with your enterprise interests.
patents granted / 23 countries
peer-reviewed papers published
patient-days of clinical safety data
regulatory pathway for lead OTC/Rx programs
Tech CMC alliance
raised to date
people in TAM, estimated $367 B market opportunity
Tech CMC alliance
raised to date
people in TAM, estimated $367 B market opportunity
With IP, data, manufacturing, and regulatory speed already in hand, PAIR is partner-ready—poised to convert trillion-dollar burdens into shared value.
PAIR repurposes two decades-proven molecules to target the mast-cell spark of inflammation—delivering low-cost, rapid-to-market solutions just as payers, regulators, and patients demand affordable, immune-friendly alternatives to expensive biologics and chronic steroids.
Co-development on new indications, regional or global licensing of lead assets, strategic capital for platform scale-up, and CMO collaborations for high-volume OTC launch.
Over 60 patents granted worldwide cover composition, ratios, and broad indications, with additional filings pending.
Two decades-safe small molecules modulate mast cells + COX-2 upstream, preserving immune function and delivering low cost of goods compared with biologics or chronic steroids.
Phase 2 readout for URI Defense (SJP-002C) and pilot human data for Metabolic Recovery (SJP-001) and Withdrawal Relief (SJP-005) total 240+ patient-days of safety; full data room accessible under NDA.
Milestone-based licensing, regional exclusivity, joint ventures, or equity-plus-royalty blends—tailored case-by-case.
SJP-001 can file via NDIN/monograph in < 24 months post-funding, leveraging established safety of components.
KVK-Tech is our strategic CMC partner, providing scale-ready capacity for both OTC and Rx programs.
We welcome thoughtful conversations with partners who share our vision for advancing global inflammatory care. If that’s you, let’s talk.